.
In discussing the study of Ananth, Vacaflor, Kekhwa, et al ., (3) Ban and Lehmann specify in detail the number of days patients spent in the trial, the mean daily dosage of chlorpromazine administered, the mean length of the first hospitalization and the average number of days spent in the hospital. The figures presented show that there were no significant differences between the two treatment groups, receiving niacin and niacinamide, and the placebo control group. Ban and Lehmann do not specify any of the results of the psychiatric rating test, the BPRS, which was used to assess the actual clinical status of the patients: they claim simply that .. . . . there was a statistically significant improvement with all three treatment regimens in the total scores of the BPRS during the entire experimental period, but no significant differences between the groups were found. "
The published research paper shows that at the end of three months of the study period (which all but five patients spent in hospital), the niacin-treated group improved in II items, the niacinamide group improved in 12 items, while the placebo group improved in only 6. At the end of the study, after two years, the two treatment groups each improved in 10 items, while the placebo group improved in 6; but by this time only six patients were still in the trial. It is true that the difference is of only 'borderline' statistical significance: based on a total of 18 BPRS items, the probability that the finding occurred by chance lies between 5 and 10 percent. Nevertheless, the clinical significance is appreciable: both treatment groups independently improved in approximately twice as many symptoms of mental illness as the placebo group.
The other means of assessing the patients in this trial, such as days in hospital, dosages of chlorpromazine, and so on, are indirect and subject to great error. The BPRS was the only direct measure of efficacy of the therapy, and it showed a large difference in favour of the treatment groups. Nevertheless, Ban and Lehmann conclude, without any qualification and without even mentioning these clinical findings, that no favourable difference for B3 over placebo was obtained in the trial.
In the trial described under "Fourth Unit Hypothesis", conducted on thirty chronically hospitalized schizophrenic patients, Ban and Lehmann note that the patients in the placebo group received a lower average daily amount of phenothiazine drugs, and less increase in the dosage of these drugs over the period of the trial. They therefore conclude that ': ... the overall therapeutic efficacy of nicotinic acid as an adjuvant medication in chronically hospitalized schizophrenic patients was found to be inferior to the overall therapeutic efficacy of an inactive placebo." (italics added). The differences in phenothiazine dosages, and in the dosage increments, were not statistically significant. Furthermore, after randomization of the patients into three groups, and before the experimental regimen was instituted, the initial daily tranquillizer dosages for the three presumably identical groups differed by more than 200 CPZ units: niacin, 367 units; niacinamide, 606 units; placebo 400 units. Yet the largest increment in dosage observed over the course of the trial was 110 CPZ units; that is, less than one-half of theerror introduced by the imperfect randomization and small sample size. Thus the differences between the B3 and the placebo groups in this respect are of no apparent statistical or clinical significance. Analysis of the results of the clinical assessment tests leads to the same conclusion (4) . Despite this, Ban and Lehmann maintain that a significant difference has been obtained in favour of the placebo group.
In referring to the trial by Ananth, Ban, Lehmann, et af., dealing with the exacerbation of psychopathology of schizophrenia by methionine (2), Ban and Lehmann acknowledge that "at first viewing" the niacin-treated group improved significantly in a two-week initial period during which phenothiazines were withdrawn, while the placebo group deteriorated. Both groups were then treated with a large amount of the methyl group donor, methionine, to test the hypothesis that niacin, by accepting methyl groups, might prevent a methionineinduced exacerbation of symptoms. Unfortunately the niacin was given in a dose which was but one-fifth of that required to absorb the methyl groups donated by 20 grams of methionine per day and both the niacin and the placebo groups deteriorated under methionine administration.
Re-evaluating the initial improvement in the niacin group, Ban and Lehmann have determined that the male-to-female ratio was not equal in the niacin and placebo groups, and they ascribed the improvement in the niacin group to ..... a sex-related phenomenon and independent of nicotinic acid administration." They further suggest that the niacin may actually have had a negative therapeutic effect since during the two weeks of methionine administration there was a greater increase in the symptoms of mental illness in the niacin group than in the placebo groups, as measured by total BPRS scores.
In fact, the observed difference, characterized as " . . . a considerably greater increase in psychopathological symptoms," does not appear to be of statistical or clinical significance; see for example, Table IV of Reference 2. Furthermore, in ascribing this negative therapeutic effect to niacin, Ban and Lehmann do not consider the possible confounding role of the sex-related phenomenon just described, which could equally well have been acting to produce this result, independent of niacin administration. Nor do they present any data exploring the possible role of such a sex-related phenomenon in confounding the results of other trials in the C.M.H.A. Study: the phenomenon is invoked only to account for a finding which shows a significant improvement in niacin-treated patients.
Ban and Lehmann discuss the results of J. R. Wittenborn's study of the effects of niacin in a group of subacute schizophrenic patients, and report that there were no significant differences between the treatment and placebo groups (6) . In a more recent communication (7) Wittenborn has described a large homogeneous subgroup of the patients, identifiable by certain features of their premorbid history, who apparently responded specifically to niacin. Patients with these features who were in the placebo group did not improve. Since this group was identified retrospectively, Wittenborn recommends follow-up studies.
In the most recently published C.M.H.A. trial, which was not discussed by Ban and Lehmann in their report, there were some indications of an additive effect when niacin and pyridoxine (vitamin B6) are used together. The amount of pyridoxine used in the trial was only 75mg per day, which is one-fifth to one-tenth the amount customarily used by orthomolecular psychiatrists (4) .
Twelve trials are planned in the C.M.H.A. Study; when the results of the five completed ones are viewed together, it becomes apparent that they are not nearly as negative as Ban and Lehmann have made them out to be in their report. Their interpretation of the data appears to be coloured, in that improvements observed in the treatment groups are either downplayed or ignored in two studies, while in other studies insignificant and meaningless differences are interpreted as demonstrating a significant difference in favour of the placebo group.
Nevertheless, it is quite true that (despite several suggestive findings) the overall effect of B3 in the C.M.H.A. Study, to date, has been significantly less than the effect obtained by orthomolecular psychiatrists. The possible reasons for the differing results must be brought out if anything is to be learned from the research. It has been pointed out (4) that the C.M.H.A. trials do not replicate the original double blind, randomized, placebo-controlled trials conducted by Abram Hoffer, Humphry Osmond and their collaborators, in that ECT was not employed. The early clinical experience indicated that ECT and B3 have significant potentiating effects on one another (4) . Nor have the more recent effective methods used in orthomolecular psychiatry been explored, in that:
• Only small doses of B3 have been employed, usually three grams daily. The dosages used clinically by orthomolecular psychiatrists range from three to nine or more grams per day. There is marked individual variability in the response to B3, a fact well established in relation to the hypocholesterolemic effects of niacin (5).
• Ascorbic acid (vitamin C) and some other members of the B vitamin group, particularly pyridoxine, have not been employed (pyridoxine was used in one study, but in minute amounts).
• Certain elementary dietary manipulations, such as the restriction of refined carbohydrates, have been neglected. 
